Literature DB >> 20729942

Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles.

Nathan S Trookman, Ronald L Rizer, Rosanne Ford, Elizabeth Ho, Vincent Gotz.   

Abstract

OBJECTIVE: To evaluate the efficacy and tolerance of a novel line treatment for periocular and perioral wrinkles. The line treatment was formulated with multiple growth factors, antioxidants, and a collagen-building peptide-ingredients that have been shown to increase collagen levels and provide long-term aesthetic benefits. To help provide immediate smoothing effects, hyaluronic acid filling spheres and a muscle contraction-inhibiting peptide were also included in the formulation.
DESIGN: Three-month, single-center, open-label, clinical study with clinical assessments at Baseline, Minutes (within 15 minutes of initial application), Month 1, and Month 3. TREATMENT: Subjects treated periocular and perioral wrinkles twice daily for three months with the line treatment. PARTICIPANTS: Thirty-seven females, 33 to 45 years of age, with mild-to-moderate, fine and coarse periocular and perioral wrinkles, were enrolled in the study. MEASUREMENTS: Investigator assessments of fine and coarse periocular and perioral wrinkles, digital photography, and tolerance assessments were conducted at all visits. Subject self-assessment questionnaires were conducted within 15 minutes of initial application and at Month 3.
RESULTS: Investigator assessments of both periocular and perioral wrinkles showed statistically significant improvements over Baseline within minutes of initial application; these positive findings continued to improve through Months 1 and 3 (all P</=0.0003). No treatment-related adverse events were reported.
CONCLUSIONS: The results from this study demonstrate that this uniquely formulated line treatment was well tolerated and provided both immediate and long-term improvements in the appearance of fine and coarse wrinkles.

Entities:  

Year:  2009        PMID: 20729942      PMCID: PMC2923951     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  20 in total

Review 1.  Coenzyme Q10, a cutaneous antioxidant and energizer.

Authors:  U Hoppe; J Bergemann; W Diembeck; J Ennen; S Gohla; I Harris; J Jacob; J Kielholz; W Mei; D Pollet; D Schachtschabel; G Sauermann; V Schreiner; F Stäb; F Steckel
Journal:  Biofactors       Date:  1999       Impact factor: 6.113

Review 2.  Insights into MMP-TIMP interactions.

Authors:  W Bode; C Fernandez-Catalan; F Grams; F X Gomis-Rüth; H Nagase; H Tschesche; K Maskos
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

Review 3.  Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology.

Authors:  J E Murphy-Ullrich; M Poczatek
Journal:  Cytokine Growth Factor Rev       Date:  2000 Mar-Jun       Impact factor: 7.638

4.  Efficacy of novel skin cream containing mixture of human growth factors and cytokines for skin rejuvenation.

Authors:  Michael H Gold; Mitchel P Goldman; Julie Biron
Journal:  J Drugs Dermatol       Date:  2007-02       Impact factor: 2.114

Review 5.  The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure.

Authors:  Jouni Uitto
Journal:  J Drugs Dermatol       Date:  2008-02       Impact factor: 2.114

Review 6.  [Clinical applications of hyaluronic acid].

Authors:  Ryszard Galus; Marek Antiszko; Paweł Włodarski
Journal:  Pol Merkur Lekarski       Date:  2006-05

7.  Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor.

Authors:  J J McArdle; T L Lentz; V Witzemann; H Schwarz; S A Weinstein; J J Schmidt
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

8.  Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts.

Authors:  P Brenneisen; J Wenk; L O Klotz; M Wlaschek; K Briviba; T Krieg; H Sies; K Scharffetter-Kochanek
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

Review 9.  Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions.

Authors:  Patricia K Farris
Journal:  Dermatol Surg       Date:  2005-07       Impact factor: 3.398

10.  Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts.

Authors:  J Varga; J Rosenbloom; S A Jimenez
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

View more
  5 in total

1.  Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream.

Authors:  Jordan Debono; Bing Xie; Aude Violette; Rudy Fourmy; Marc Jaeger; Bryan G Fry
Journal:  J Mol Evol       Date:  2016-11-18       Impact factor: 2.395

Review 2.  Perioral rejuvenation: restoration of attractiveness in aging females by minimally invasive procedures.

Authors:  Uwe Wollina
Journal:  Clin Interv Aging       Date:  2013-09-02       Impact factor: 4.458

3.  The Comparative Evaluation of Fermented and Non-fermented Soybean Extract on Antioxidation and Whitening.

Authors:  Ga Yeon Chae; Bae Jin Ha
Journal:  Toxicol Res       Date:  2011-12

Review 4.  Collagen Hydrolysates for Skin Protection: Oral Administration and Topical Formulation.

Authors:  Gabriel Aguirre-Cruz; Arely León-López; Verónica Cruz-Gómez; Rubén Jiménez-Alvarado; Gabriel Aguirre-Álvarez
Journal:  Antioxidants (Basel)       Date:  2020-02-22

5.  Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care.

Authors:  Ignacio Mejía-Calvo; Leonardo E López-Juárez; Said Vázquez-Leyva; Carlos A López-Morales; Daniel Montoya-Escutia; Pamela G Merlos Rivera; José Enrique Herbert-Pucheta; Luis Gerardo Zepeda-Vallejo; Marco Velasco-Velázquez; Lenin Pavón; Sonia M Pérez-Tapia; Emilio Medina-Rivero
Journal:  J Cosmet Dermatol       Date:  2020-05-10       Impact factor: 2.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.